FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm

June 7, 2021 by Reece Nations
In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

SILVER SPRING, Md. — The Food and Drug Administration on Monday granted its approval to aducanumab, an Alzheimer’s treatment developed by Biogen for use in patients, despite mixed clinical trial results for the drug. 

Prescribed under the brand name “Aduhelm,” the treatment is given intravenously and is meant to remove protein deposits from the brains of patients in the early stages of Alzheimer’s. The proteins are known to cause loss of memory and physical control over one’s body functions.

The effects of the drug were studied in two clinical trials — only one of which deemed Aduhelm as an effective treatment. Prior to its approval, experts on the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee concluded that it was unreasonable to maintain the clinical benefit of one successful trial as the primary evidence supporting its approval.

“We are well-aware of the attention surrounding this approval,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a written statement. “We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review.”

Cavazzoni continued, “Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.”

In all of its evaluations, the FDA noted Aduhelm “consistently and very convincingly” led to a reduction in the level of amyloid plaques in patient’s brains on a “dose- and time-dependent” basis. Ultimately, the administration concluded the drug satisfied the standards of its “Accelerated Approval” pathway and was likely to produce clinical benefit.

Roughly 40% of trial participants experienced brain bleeding or swelling after receiving high doses of the drug, according to study results published by Biogen. Although most participants were either asymptomatic or experienced only headaches, dizziness or nausea, the effects of the drug caused 6% of high-dose recipients to withdraw from the study.

“We ultimately decided to use the Accelerated Approval pathway — a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit,” Cavazzoni continued in the FDA’s statement. “In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.”

The drug will now undergo a post-market study to determine its widespread effectiveness as an Alzheimer’s treatment. If the “Phase 4 trial” fails to demonstrate its effectiveness or leads to adverse health effects in patients, the FDA could subsequently rescind its approval — although it is not required by law.

Aduhelm is the first new Alzheimer’s treatment approved by the FDA since 2003. Roughly six million Americans and 30 million people worldwide have Alzheimer’s, according to analysis by the Alzheimer’s Association. Further, the number of new cases of Alzheimer’s and other dementias is expected to double annually by 2050.

“The consequences of FDA approval are as disturbing as they are vast,” Jason Karlawish, professor of Medicine and Medical Ethics and Senior Fellow of the Center for Bioethics at the University of Pennsylvania, wrote in an op-ed for Stat News. “Around two million Americans could be prescribed aducanumab, at an estimated cost that ranges from $20,000 to $50,000 per person per year. Biogen claims the benefits of slowing declines in cognition and day-to-day function are worth this price. I think the company is wrong, and I agree with the analyses by the Institute for Clinical and Economic Review; the data to make this case are murky and, even if they were clear, the drug’s benefits are ambiguous at best and not worth this cost. Putting it on the market will stress Medicare’s resources.”

In The News

Health

Voting

Health

Biden Pressured to Reverse Title 42 by End of Month
Travel
Biden Pressured to Reverse Title 42 by End of Month
June 23, 2021
by Alexa Hornbeck

The Biden administration is being pressured to decide by the end of the month as to whether to reverse Title 42, known as the Public Health Service Act, used to restrict non-essential travel across the U.S.-Mexico border to prevent the spread of COVID-19.  In March 2020,... Read More

Faith-based Approaches Can Overturn Vaccine Hesitancy
Health
Faith-based Approaches Can Overturn Vaccine Hesitancy
June 23, 2021
by Alexa Hornbeck

A recent survey conducted by the Public Religion Research Institute and Interfaith Youth Core finds that faith-based approaches supporting vaccine uptake can influence members of key hesitant groups to get vaccinated. Religious leaders can help overturn hesitancy by battling popular assumptions that groups like QAnon have... Read More

W.A.T.C.H. Report for Toys to Avoid This Summer
Health
W.A.T.C.H. Report for Toys to Avoid This Summer
June 23, 2021
by Alexa Hornbeck

This week marked the official beginning of summer, and in preparation, the World Against Toys Causing Harm, known as W.A.T.C.H., produced a Summer Safety Report for parents and caregivers to navigate summer heat safety for children whose injuries typically double during the summer months. “We want... Read More

New WHO Guidance Seeks Sharp Reduction in Suicide Rate
Mental Health
New WHO Guidance Seeks Sharp Reduction in Suicide Rate
June 23, 2021
by Alexa Hornbeck

The World Health Organization released new suicide prevention guidance last week aimed at reducing the world’s suicide rate by a third by 2030. “While a comprehensive national suicide prevention strategy should be the ultimate goal for all governments,” said Dr. Alexandra Fleischmann, suicide prevention expert at... Read More

SBA Chief Says Ensuring Equity Critical to Success of COVID Relief Program
Business
SBA Chief Says Ensuring Equity Critical to Success of COVID Relief Program
June 22, 2021
by Kate Michael

WASHINGTON — While much good came from the COVID relief funds doled out by the Small Business Administration as the pandemic ran its course time has shown that certain businesses -- particularly those owned by women and minorities -- went underserved in the earlier aid rounds.... Read More

DOD Advised to Provide Congress With More Info On PFAS Costs
Defense
DOD Advised to Provide Congress With More Info On PFAS Costs
June 22, 2021
by Dan McCue

WASHINGTON - Despite being in the early phases of an investigation into PFAS contamination at nearly 700 U.S. military installations, the Department of Defense says the future environment clean-up of these facilities will cost at least $2.1 billion and likely much more. That number has not... Read More

News From The Well
scroll top